GPCR
Structure Therapeutics Inc.
Biotechnology · Healthcare · United States
21.87
close · 2026-10-30
value
87
cheaper than peers87
quality
95
stronger fundamentals95
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -6.3% | 82 |
| cash flow yield, 3 years ago | -3.0% | 78 |
| earnings yield, latest year | -9.1% | 75 |
| price to book | 1.15× | 73 |
| earnings yield, 2 years ago | -11.1% | 73 |
| earnings yield, 1 year ago | -9.8% | 73 |
| cash flow yield, 2 years ago | -5.2% | 69 |
| cash flow yield, 1 year ago | -7.6% | 67 |
| cash flow yield, latest year | -14.5% | 55 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -15.0% | 97 |
| debt to equity | 0.4% | 85 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$104.2M |
| employees | 233 |
| first trade | 2023-02-03 |
| next earnings | not reported |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.99 | -2.14 | -2.43 | -1.38 |
| free cash flow | -$225.8M | -$117.9M | -$81.7M | -$46.3M |
| net income | -$141.2M | -$122.5M | -$89.6M | -$51.3M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $10.2M | $0 | $0 | not reported |